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Abstract
Extracellular matrix factors within the tumor microenvironment that control resistance to chemotherapeutics are poorly
understood. This study focused on understanding matrix adhesion pathways that control the oral carcinoma response to
cisplatin. Our studies revealed that adhesion of HN12 and JHU012 oral carcinomas to carcinoma matrix supported tumor cell
proliferation in response to treatment with cisplatin. Proliferation in response to 30 mM cisplatin was not observed in HN12
cells adherent to other purified extracellular matrices such as Matrigel, collagen I, fibronectin or laminin I. Integrin b1 was
important for adhesion to carcinoma matrix to trigger proliferation after treatment with cisplatin. Disruption of talin
expression in HN12 cells adherent to carcinoma matrix increased cisplatin induced proliferation. Pharmacological inhibitors
were used to determine signaling events required for talin deficiency to regulate cisplatin induced proliferation.
Pharmacological inhibition of NF-kB reduced proliferation of talin-deficient HN12 cells treated with 30 mM cisplatin. Nuclear
NF-kB activity was assayed in HN12 cells using a luciferase reporter of NF-kB transcriptional activity. Nuclear NF-kB activity
was similar in HN12 cells adherent to carcinoma matrix and collagen I when treated with vehicle DMSO. Following
treatment with 30 mM cisplatin, NF-kB activity is maintained in cells adherent to carcinoma matrix whereas NF-kB activity is
reduced in collagen I adherent cells. Expression of talin was sufficient to trigger proliferation of HN12 cells adherent to
collagen I following treatment with 1 and 30 mM cisplatin. Talin overexpression was sufficient to trigger NF-kB activity
following treatment with cisplatin in carcinoma matrix adherent HN12 cells in a process disrupted by FAK siRNA. Thus,
adhesions within the carcinoma matrix create a matrix environment in which exposure to cisplatin induces proliferation
through the function of integrin b1, talin and FAK pathways that regulate NF-kB nuclear activity.
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Introduction
Nearly 80% of stage III and IV oral and tongue cancers are
resistant to cisplatin based chemotherapies [1,2]. In breast, ovarian
and lung cancers, the composition of the tumor stroma changes
during tumorigenesis. Changes in the tumor stroma include
enhanced deposition of matrix proteins such as laminin and
collagen, an increase in remodeling of the matrix associated with
an increase in fibrillar content and an increase in stromal rigidity
or mechanical tension. These changes have been linked to
promoting tumor cell progression, motility, invasion and resistance
to chemotherapeutic agents [3,4,5,6,7,8].
Fibroblasts isolated from the stroma of different staged breast
tumors have been utilized to generate tumor-fibroblast matrices
[9]. Adhesion of cancer cell lines to these fibroblast matrices is
sufficient to confer resistance to chemotherapeutics. However, it is
currently not known whether carcinomas secrete a matrix that is
sufficient to control chemoresistance. Integrins mediate adhesion
to extracellular matrices and in breast cancer cell lines, integrin b1
function is required for adhesion to tumor-fibroblast matrices to
induce chemoresistance [9,10,11]. It is currently not known
whether oral carcinoma integrins and integrin downstream
signaling pathways control chemoresistance while adherent to
the carcinoma matrix [12,13].
Talin and Src are proteins that associate with integrin cyto-
plasmic domains in oral carcinomas and function in adhesion-
dependent processes [14,15,16,17]. Src downstream signaling
regulates survival, apoptosis, spreading, invasion and metastasis
[12,14,18]. In an embryonic epitheliod cell line, constitutively active
Src and integrin b1 cooperatively regulate cisplatin chemosensitivity
[12]. Knockdown of Src was recently found to inhibit matrigel
invasionandproliferationinoralcarcinomacells[17].InMEFs,Src
induces resistance to cisplatin by modulation of connexin 43
function in cell-cell contacts [19]. In ovarian carcinomas with
constitutively active Src and FAK, treatment with pharmacological
inhibitors of Src reduce survival of cisplatin treated cells [18].
Whether integrin b1 and Src cooperatively signal during the oral
carcinoma response to cisplatin is poorly understood.
Talin functions in prostate cancer invasion, metastasis and
anoikis or cell death induced by detachment from the matrix [20].
Studies in our lab demonstrate that knockdown of talin in oral
carcinoma cells inhibits matrigel invasion, disrupts spreading on
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cisplatin chemoresistance [17]. Signaling events elicited by
adhesion to the carcinoma matrix that are dependent on talin
function in oral carcinomas are poorly understood.
A disruption of talin expression in fibroblasts reduces FAK
activation [21] and the overexpression of talin in a prostate tumor
cell line activates FAK, Src and Akt signaling [20]. Talin
overexpression was recently linked to a high risk for aggressive
oral carcinomas [22]. In addition, overexpression of a talin head
domain that is defective in integrin activation results in the
reduction of Src, FAK and PI-3K signaling in oral carcinomas
[22]. Adhesion of breast carcinoma lines to tumor fibroblast-
matrices induces similar levels of FAK activation regardless of
whether the cell lines are chemosensitive or chemoresistant
suggesting that the levels of adhesion induced FAK activity do
not correlate with chemoresistance and furthermore, it is possible
that FAK-independent pathways regulate chemoresistance in
breast carcinomas [9,11]. The role of FAK in the oral carcinoma
response to cisplatin while adherent to carcinoma matrix is poorly
understood.
Our current studies examined whether adhesion to the matrix
secreted by cisplatin resistant oral carcinoma cells (carcinoma
matrix) is sufficient to alter tumor cell behavior following exposure
to cisplatin. Our findings demonstrate that adhesion to carcinoma
matrix was sufficient to signal for proliferation following treatment
with cisplatin. This was observed in two oral carcinoma cell lines, a
cisplatin resistant HN12 (IC50 10 mM) [23] and a cisplatin
sensitive JHU012 (IC50 1 mM) [24]. We studied the requirement
for oral carcinoma integrin b1 in the proliferative response to
cisplatin of carcinoma matrix adherent cells. We focused on the
signaling events that connect matrix adhesion to cisplatin induced
proliferation and detected a role for NF-kB signaling in the
response to cisplatin. Due to the role of integrins and NF-kB in the
matrix adhesion response we examined whether talin regulates
both cisplatin induced proliferation and NF-kB signaling. Our
studies show that integrin b1, talin and FAK regulate NF-kB
signaling and cisplatin induced proliferation for oral carcinomas
adherent to carcinoma matrix.
Results
Adhesion to carcinoma matrix and integrin b1 control
cisplatin induced proliferation of oral carcinomas
It was not certain whether adhesion to matrix secreted by oral
carcinoma cells is sufficient to alter the tumor cell response to
cisplatin. Previous reports indicate that cisplatin at a dose of 10 mM
fails to change proliferation of HN12 cells in a conventional culture
system with medium containing serum [23]. To study the role of the
carcinoma matrix, cisplatin resistant HN12 cells [23] were seeded
onto tissue culture dishes coated with carcinoma matrix. Prolifer-
ation of replated cells was assayed by MTT and compared in the
presence of vehicle DMSO and cisplatin. Proliferation was assayed
for cells adherent to carcinoma matrix in serum-free medium
(Figure 1A). To monitor whether tumor cell adhesion independent
of the carcinoma matrix is sufficient to control the response to
cisplatin, cells were replated onto BSA and collagen coated wells.
Treatment of the adherent HN12 cells with 1 mM cisplatin induced
proliferation on BSA 1.52-fold (p=0.007) and on collagen I 1.73-
fold (0.5 and 5 mg collagen respectively, p=0.0046 and 0.0007).
Adhesion to collagen I and treatment with cisplatin at 30 mM
reduced proliferation 49% compared to DMSO-treated cultures
(0.5, 5.0 and 50 mg/ml collagen respectively, p=0.001, 0.0002 and
0.0006). In HN12 cells adherent to carcinoma matrix, treatment
with cisplatin at 1 mM increased proliferation 2.97-fold (p=0.01)
whereas 30 mM cisplatin induced proliferation 1.32-fold (p=0.07).
Thus, adhesion to the carcinoma matrix and treatment with
cisplatin induces tumor cell proliferation in serum-free medium.
The ability of 1 mM cisplatin to induce proliferation of HN12
cells adherent to collagen I was confirmed using a second assay for
proliferation, we determined the percentage of nuclei positive for
the proliferation antigen, Ki67. Fluorescent images of the anti-
Ki67 immunofluorescence stained HN12 cells are shown
(Figure 1B). The percentage of nuclei positive for Ki67 increased
1.63-fold (p,0.005) after treatment with 1 mM cisplatin for 48
hours and treatment with 30 mM cisplatin reduced the percentage
of Ki67 positive nuclei by 45% (p,0.005) (Figure 1C). The results
of the Ki67 nuclear staining reproduced the MTT observations
suggesting that adhesion to the carcinoma matrix and treatment
with cisplatin indeed induces proliferation of HN12 cells.
The carcinoma matrix contains basement membrane proteins
such as collagens, laminins and fibronectin [25,26]. It seemed
likely that adhesion to these purified matrix proteins or Matrigel, a
basement membrane extract from EHS tumors [27], would
similarly mediate cisplatin induced proliferation. HN12 cells
adherent to purified preparations of BSA, Matrigel, laminin I,
fibronectin or collagen I were treated with DMSO or 30 mM
cisplatin and 48 hours later proliferation was assayed by MTT.
Treatment with 30 mM cisplatin reduced proliferation for cells
adherent to BSA by 41% (p=0.002), Matrigel 47.5% (p=0.012),
laminin I 38.8% (p=0.001), fibronectin 46.9% (p=0.009) and
collagen I 48.9% (p=0.012) (Figure 1D). Thus, adhesion to
carcinoma matrix and treatment with 30 mM cisplatin induces
tumor cell proliferation, a phenotype that is not observed for
HN12 cells adherent to a variety of purified matrix proteins or
basement membrane extract.
It is possible that HN12 cells have an aberrant proliferative
response to cisplatin because of their known resistance to cisplatin.
To test this possibility, the response to cisplatin was studied in the
oral carcinoma cell line JHU012 that is relatively more sensitive to
cisplatin sensitive (IC50 1 mM) [24]. JHU012 cells replated on the
carcinoma matrix were treated with a wider range of cisplatin
concentrations (0.05, 1, to 30 mM) because of the greater cisplatin
sensitivity of these cells. Surprisingly, in JHU012 cells the cisplatin
response at 0.05 and 1 mM was an induction of proliferation (3.25-
and 2.77-fold, respectively p=0.0008 and 0.0046) (Figure 2A).
Treatment with 30 mM cisplatin induced proliferation 1.32-fold
(p=0.044). As a control, the JHU012 cells were seeded onto
collagen I. JHU012 proliferation was induced in response to
cisplatin at 0.05 and 1 mM (3.16- and 2.32-fold respectively,
p=0.0022 and 0.00018). Treatment with 30 mM cisplatin in the
collagen adherent cells failed to reduce JHU012 proliferation
below the levels in DMSO treated cells (1.40-fold induction,
p=0.107). Adhesion to carcinoma matrix or collagen I and
treatment with cisplatin induces proliferation of JHU012 cells.
It was not clear whether integrin b1 function is required for
cisplatin to induce proliferation of JHU012 cells adherent to
carcinoma matrix or collagen. JHU012 cells deficient in integrin b1
expression were assayed for the response to cisplatin while adherent
to carcinoma matrix (Figure 2A) or collagen (Figure 2B). JHU012
cells deficient in integrin b1 attached to the carcinoma matrix and
collagen I similar to the parental JHU012 cells (data not shown).
Reduction in the surface levels of integrin b1 in the integrin b1
deficient JHU012 cells was shown by flow cytometry (Figure 2C).The
mean fluorescence intensity for surface levels of integrin b1 in
JHU012controlandintegrinb1-/- cellsis3704 and 396, respectively,
indicating a 9.35-fold reduction in integrin b1 expression.
Treatment of integrin b1 deficient JHU012 cells with 0.05 or
1 mM cisplatin while adherent to carcinoma matrix induced
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21496Figure 1. The carcinoma matrix mediates cisplatin induced tumor cell proliferation. The proliferation of HN12 cells adherent to matrix
proteins following treatment with vehicle DMSO or cisplatin for 48 hours is shown. A. Proliferation of HN12 cells adherent to BSA (0.1%), collagen I
(0.5, 5.0 and 50.0 mg/mL) or carcinoma matrix. Proliferation is normalized to DMSO-treated cells for each substratum. B. Ki67 staining of HN12 cells
adherent to collagen and treated with DMSO or cisplatin (1 and 30 mM). Shown are representative fluorescent images of the anti-Ki67 and control
secondary antibody staining. The nuclear compartment was visualized by co-staining with DAPI. C. Shown in the bar graph is the mean percentage of
HN12 nuclei that are positive for Ki67 in HN12 cells adherent to collagen and treated with vehicle DMSO or cisplatin (1 and 30 mM). Error bars indicate
standard deviations. D. Proliferation of HN12 cells adherent to BSA (0.1%), matrigel, laminin I, fibronectin or collagen I (10 mg/mL) and treated with
vehicle DMSO or 30 mM cisplatin. Error bars on the mean proliferation are standard deviations. These experiments were performed in three separate
trials in quadruplicate. Student’s t-test p values, *p,0.05, **p,0.01, ***p,0.005.
doi:10.1371/journal.pone.0021496.g001
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Parental JHU012 cells induced proliferation 3.25- and 2.77-fold
(comparison of JHU012 parental to integrin b1 deficient at 0.05
and 1 mM cisplatin, p=0.003 and 0.0098) (Figure 2A). After
treatment with 30 mM cisplatin, cell proliferation was reduced by
7% in the integrin b1 deficient cells (p=0.14). Thus, if adherent to
carcinoma matrix, integrin b1 is required for maximal oral
carcinoma proliferation in response to 0.05, 1 and 30 mM
cisplatin.
Integrin b1 deficient JHU012 cells adherent to collagen and
treated with either 0.05 or 1 mM cisplatin resulted in similar levels
of proliferation (2.71- and 2.46-fold respectively (p=0.0009,
0.0002)) (Figure 2B). Comparison of the proliferation of JHU012
parental and integrin b1 deficient lines adherent to collagen after
treatment with cisplatin at 0.05 and 1 mM revealed no significant
alteration in the levels of proliferation in integrin b1 deficient cells
(p=0.233 and 0.135). Exposure to 30 mM cisplatin reduced
proliferation in the integrin b1 deficient JHU012 cells adherent to
collagen by 18% (p=0.011). Thus, integrin b1 function is required
for collagen adherent JHU012 cell proliferation in response to
30 mM cisplatin.
Our data demonstrates that JHU012 cells adherent to
carcinoma matrix require integrin b1 for cisplatin induced
proliferation. In JHU012 cells adherent to collagen I, 30 mM
cisplatin induces integrin b1 dependent proliferation. In contrast,
treatment with a lower dose of cisplatin at 1 mM induces
proliferation independent of integrin b1. Cisplatin at 1 mM may
induce proliferation of collagen adherent cells through either
integrin receptor dependent or non-integrin receptor mechanisms.
Proteins secreted by the carcinoma during 3 days in culture may
engage integrin b receptors in addition to integrin b1 and these
integrins may promote cisplatin induced proliferation. Alterna-
tively, non-integrin receptor pathways may induce proliferation
following treatment with cisplatin such as the EGFR [28].
It was subsequently determined whether integrin b1 is important
for cisplatin induced proliferation in HN12 cells adherent to
carcinoma matrix. HN12 cells adherent to carcinoma matrix with
a targeted disruption of integrin b1 display a reduction in cisplatin
induced proliferation compared to control siRNA transfectants
following treatment with 1 mM cisplatin (p=0.0005) (relative
proliferation 1 mM cisplatin:DMSO for integrin b1 knockdowns
1.41-fold, p=0.0023, for the control siRNA 1.92-fold p=0.012)
(Figure 2D). Thus, integrin b1 is required for cisplatin to induce
maximal proliferation of HN12 and JHU012 cells adherent to
carcinoma matrix.
Intracellular pathways involved in cisplatin induced
proliferation
Due to the known cellular roles of talin and Src and their
functions in integrin signaling, talin and Src were likely candidates
to control cisplatin induced proliferation mediated by adhesion to
the carcinoma matrix [12,14,15,18,20,29]. The expectation was
talin or Src knockdown would alter integrin signaling and reduce
cisplatin induced proliferation. HN12 cells transfected with
siRNA-duplexes reduced the steady-state protein levels of talin
and Src by approximately 80% (Figure 3B). Control siRNA
transfectants and HN12 cells with targeted reductions of talin and
Src were replated onto carcinoma matrix and adherent cells
incubated with vehicle DMSO or cisplatin (1 and 30 mM) for 48
hours. Proliferation was assayed by MTT (Figure 3A). In control
HN12 cells, 1 mM cisplatin increased proliferation 2.96-fold
(p=0.001). Proliferation was induced 1.32-fold (p=0.07) after
treatment with 30 mM cisplatin. Knockdown of Src induced
proliferation 1.88-fold (p=0.1) with 1 mM cisplatin and failed to
change proliferation with 30 mM cisplatin. In contrast, knockdown
of talin and exposure to 1 mM cisplatin increased proliferation
4.64-fold (p=0.02) relative to the DMSO-treated cells. Treatment
with 30 mM cisplatin in the talin knockdowns increased prolifer-
ation 2.28-fold (p=0.01) compared to DMSO-treated cells.
Furthermore, JHU012 cells adherent to carcinoma matrix with
targeted reduction of talin show increased proliferation in
comparison to control siRNA transfectants after treatment with
30 mM cisplatin (data not shown). Thus, knockdown of talin
increased proliferation induced by cisplatin in HN12 and JHU012
cells adherent to carcinoma matrix.
To further understand the pathways important for proliferation
of cisplatin treated cells we tested whether pharmacological
inhibitors that target certain signaling pathways will disrupt
HN12 proliferation after treatment with cisplatin. Pharmacolog-
ical inhibitors were selected that target pathways shown by other
investigators to regulate chemoresistance in a variety of cellular
systems. The selected inhibitors targeted NF-kB (MG-132, a non-
specific proteasomal inhibitor) [30] , PI3-K (LY294002) [31],
caspases (ZVAD-FMK) [32] and ERK (PD98059) [33,34].
HN12 cells with siRNA knockdown of talin, and control siRNA
transfected cells, were treated with DMSO plus an inhibitor
(Figure 3C) or 30 mM cisplatin plus an inhibitor (Figure 3D) and
proliferationwas assayed 48 hours later.In DMSO-treatedcells, the
disruption of talin expression reduced proliferation by 37.5%
(p=0.018). In the presence of DMSO each of the tested inhibitors
similarly altered proliferation in the control and talin knockdowns.
MG-132reduced proliferationincontrolcellsby94.5%(p=0.0004)
and in talin knockdowns 93.1% (p=0.0008). LY294002 reduced
proliferation in control cells by 44.6% (p=0.012) and in talin
knockdowns 26.5% (p=0.028). ZVAD-FMK or PD98059 reduced
proliferation in control cells by 24.2% and 30.0% respectively
(p=0.034, 0.011). In the talin knockdowns ZVAD-FMK or
PD98059 reduced proliferation 11.6% and 15.8% (p=0.0135,
0.0358). This data suggests that HN12 cell proliferation of talin
knockdowns and control cells have similar sensitivity to MG-132
and LY294002.
In the presence of 30 mM cisplatin (Figure 3D) control and talin
deficient cells have distinct responses to ZVAD-FMK and PD98059.
In control siRNA transfectants, treatment with 30 mM cisplatin and
either ZVAD-FMK or PD98059 increased proliferation 1.91-fold
(p=0.007 and 0.023) suggesting that inhibition of caspases or ERK
pathways leads to enhanced proliferation of cisplatin treated cells. In
contrast, ZVAD-FMK with 30 mM cisplatin did not significantly
Figure 2. Role of integrin b1 in cisplatin induced oral carcinoma proliferation. Proliferation of JHU012 and JHU012 integrin b1 deficient cells
adherent to A. carcinoma matrix and B. collagen I (10 mg/mL). Cells were treated for 48 hours with DMSO or cisplatin (0.05, 1, 30 mM) as indicated.
Shown in the bar graph is the mean proliferation and error bars that indicate standard error. The horizontal line indicates the proliferation of control
JHU012 cells after treatment with 30 mM cisplatin. Statistical comparisons for each substratum, a=JHU012/DMSO, b=JHU012/0.05 mM, c=JHU012/
1 mM, d=JHU012/30 mM. C. Analysis of surface expression levels of integrin b1, a2 and a6 subunits in JHU012 and JHU012 b1 deficient cells by flow
cytometry. Shown are overlayed histograms, grey is the isotype control and black is the indicated integrin subunit. MFI: Mean Fluorescence Intensity.
D. Proliferation of HN12 cells adherent to carcinoma matrix. Control and integrin b1 siRNA transfected cells were treated for 48 hours with DMSO or
1 mM cisplatin as indicated. Shown in the bar graph is mean proliferation and error bars indicate standard error. Student’s t-test p values, *p,0.05,
**p,0.01, ***p,0.005.
doi:10.1371/journal.pone.0021496.g002
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p=0.153). PD98059 with 30 mM cisplatin increased proliferation of
talin deficient HN12 cells 1.25-fold (p=0.013). Treatment with
30 mM cisplatin and LY294002 did not change the proliferation of
control siRNA transfectants (1.06-fold, p=0.44) or talin knockdowns
(1.03-fold, p=0.44). Finally, MG-132 with 30 mM cisplatin triggered
in control siRNA transfectants a reduction in proliferation by 49.5%
(p=0.07) and in talin knockdowns a reduction of 58.2% (p=0.04).
Thus, DMSO and cisplatin treated cells differ in sensitivity to
LY294002, ZVAD-FMK and PD98059. MG-132 reduced prolifer-
ation of DMSO and cisplatin treated cells in control siRNA
transfectants and talin deficient cells.
Figure 3. Pharmacological inhibition of oral carcinoma proliferation. A. Proliferation of HN12 cells transfected with talin, Src or control siRNA
adherent to carcinoma matrix following treatment with vehicle DMSO or cisplatin (1 and 30 mM) for 48 hours is shown in the bar graph. B. Western
blots to analyze the levels of talin and Src in siRNA-treated HN12 cells. C. and D. HN12 cells transfected with talin or control siRNA were assayed for
proliferation 48 hours after treatment with C. vehicle DMSO and the indicated inhibitor or D. 30 mM cisplatin and the indicated inhibitor. The mean
proliferation with error bars indicating standard error are shown in the bar graph. The data was normalized in C. to control siRNA/DMSO or in D. to
control siRNA/30 mM cisplatin. Cells were treated with MG-132 20 mM, LY294002 20 mM, ZVAD-FMK 10 mM and PD98059 20 mM. E. Proliferation of
HN12 cells adherent to carcinoma matrix following treatment with 30 mM cisplatin combined with IKK scrambled peptide (67 mM), IKKb inhibitor
(67 mM) or NLS 360–369 NF-kB p50 (100 mg/ml). F. Proliferation of control siRNA transfected HN12 cells adherent to carcinoma matrix following
treatment with DMSO alone or DMSO with IKKb inhibitor (67 mM). Talin siRNA transfected HN12 cells adherent to carcinoma matrix following
treatment with DMSO alone or DMSO with IKKb inhibitor (67 mM), 1 mM cisplatin alone or 1 mM cisplatin with IKKb inhibitor (67 mM). Student’s t-test p
values *p,0.05, **p,0.01, ***p,0.005. Error bars on the mean proliferation indicate standard deviations. Experiments were performed twice in
triplicate.
doi:10.1371/journal.pone.0021496.g003
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of HN12 cells adherent to carcinoma matrix we treated adherent
cells with 30 mM cisplatin in combination with NF-kB peptide
inhibitors. The NF-kB peptide inhibitors included the IKKb
peptide inhibitor (aa T735-E745, blocks NEMO binding with IkB
kinase complex) and the NF-kB p50 nuclear localization sequences
360-369 that disrupts p50/p65 nuclear localization. Treatment
with either peptide inhibitor reduced proliferation by 60% in
comparison to the IKK scrambled peptide control (Figure 3E). We
subsequently determined whether disruption of NF-kB signaling
affects proliferation of talin deficient HN12 cells adherent to
carcinoma matrix. Talin deficient HN12 cells were treated with
DMSO or 1 mM cisplatin and the IKKb peptide inhibitor. The
NF-kB inhibitory peptide reduced proliferation of talin deficient
cells adherent to carcinoma matrix 4.22-fold and 2.08-fold
(p=0.033 and 0.006) respectively in the DMSO and 1 mM
cisplatin treated cells (Figure 4D). These results support the notion
that proliferation of cisplatin treated HN12 cells adherent to
carcinoma matrix may utilize NF-kB signaling.
One possible explanation for talin deficiency promoting
proliferation of cisplatin treated cells is talin deficiency may alter
the expression levels of regulators in the NF-kB pathway such as
increasing the steady state levels of IKKb or decreasing
ikBaexpression. The steady state levels of IKKb and ikBa in
control and talin knockdown HN12 cells were measured by
western blot analysis of lysates from HN12 cells adherent to
carcinoma matrix prior to and following treatment with cisplatin.
There was no detectable change in the steady state expression
levels of either IKKb or ikBa or the levels of serine phosphor-
ylation of IKKb or ikBa in HN12 cells with reduced expression of
talin prior to or following exposure to 30 mM cisplatin (data not
shown). Thus, talin deficiency may regulate cisplatin induced
proliferation independent of regulating the steady state levels of
IKKb or ikBa ˜.
Talin regulates nuclear NF-kB activity and cisplatin
induced proliferation
The phenotype with the pharmacological inhibitors demon-
strates that the NF-kB pathway is important for proliferation of
cisplatin treated oral carcinoma cells adherent to carcinoma
matrix and NF-kB is important for proliferation of talin deficient
cells treated with cisplatin. We were interested in whether
adhesion to the carcinoma matrix controls NF-kB signaling
following treatment with cisplatin. Our expectation was that in
cells adherent to carcinoma matrix, NF-kB signaling will increase
following treatment with cisplatin. For the collagen adherent
HN12 cells we predicted that regulation of NF-kB signaling is
independent of cisplatin. Initially, we determined the nuclear NF-
kB activity in HN12 cells adherent to carcinoma matrix or
collagen I following treatment with DMSO or cisplatin. To test
this, HN12 cells were co-transfected with (NF-kB)4 Luc, a plasmid
containing a multimerized NF-kB regulatory element that controls
transcription of a firefly luciferase gene together with a plasmid
containing renilla luciferase to normalize for transfection efficien-
cy. Transfectants were replated onto either carcinoma matrix or
collagen I and adherent cells were treated with DMSO or cisplatin
at 30 mM for 24 hours. Renilla normalized firefly luciferase
activity was determined for each condition. Similar levels of NF-
kB activity were detected in vehicle DMSO-treated HN12 cells
adherent to collagen I or carcinoma matrix. Following treatment
with 30 mM cisplatin, NF-kB activity was reduced by 65%
(p=0.09) in cells adherent to collagen. NF-kB activity was
sustained for cells adherent to carcinoma matrix after treatment
with 30 mM cisplatin (1.17-fold increase, p=0.18) (Figure 4A).
Thus, adhesion to carcinoma matrix, in contrast to collagen,
signals for maintenance of NF-kB signaling in oral carcinoma after
exposure to 30 mM cisplatin.
Based on our observation that proliferation increases in talin
deficient cells following treatment with cisplatin, we predicted that
overexpression of talin should inhibit cisplatin induced prolifera-
tion and reduce NF-kB signaling. Since cisplatin induces the
activity of calpains and caspases that proteolytically cleave talin,
we tested whether overexpression of wild-type and calpain
cleavage-resistant talin (talin 432G) [35] are sufficient to inhibit
NF-kB activity. In this experiment, HN12 cells were co-transfected
with plasmids containing (NF-kB)4 firefly luciferase and renilla
luciferase in combination with either the empty vector control
cDNA3.1, talin cDNA or talin432G cDNA. The transfectants
were replated on carcinoma matrix and treated with vehicle
DMSO and the levels of renilla normalized firefly luciferase
activity are shown (Figure 4B). Similar levels of NF-kB activity
were observed in wild-type talin and control cDNA 3.1
transfectants. Expression of talin432G unexpectedly increased
nuclear NF-kB activity 2.19-fold (p=0.031). Hence, overexpres-
sion of cleavage-resistant talin432G regulates NF-kB activity in
oral carcinoma adherent to carcinoma matrix in the absence of
cisplatin.
Since adhesion to the carcinoma matrix regulates NF-kB
activity following treatment with cisplatin and overexpression of
talin can control NF-kB activity it seemed possible that cisplatin
treatment of talin overexpressing cells adherent to carcinoma
matrix may influence nuclear NF-kB activity. We were interested
in determining whether talin overexpression controls NF-kB
signaling after exposure to cisplatin in a matrix-specific manner.
To test this, HN12 cells were transfected with NF-kB firefly
luciferase, renilla luciferase and talin cDNA. Transfected cells
were replated onto carcinoma matrix or collagen I and adherent
cells were treated with DMSO or cisplatin (30 mM) and the
normalized firefly luciferase activity assayed 24 hours later.
Unexpectedly, in cells overexpressing talin and adherent to
carcinoma matrix, treatment with cisplatin triggered a 6.5 fold
induction of NF-kB reporter activity (Figure 4C). In contrast, when
the transfectants were plated on collagen, treatment with cisplatin
failed to induce NF-kB activity. Thus, overexpression of talin in
HN12 cells regulates NF-kB activity following treatment with
cisplatin in a carcinoma-matrix specific manner. There was no
significant difference in NF-kB levels on collagen for DMSO and
cisplatin treated cells indicating that overexpression of talin
prevented the cisplatin induced reduction of NF-kB signaling for
collagen I adherent cells.
It is possible that talin overexpression in cooperation with
cisplatin treatment alters gene expression and may increase basal
promoter activity. To test this possibility, talin was overexpressed
in HN12 cells and the activity of the minimal TK promoter
driving firefly luciferase activity was assayed following treatment
with cisplatin and DMSO. This mimimal promoter lacks the
upstream multimerized NF-kB cis regulatory element. HN12 cells
transfected with talin cDNA, TK-firefly luciferase and renilla
luciferase were replated on carcinoma matrix and treated with
DMSO or cisplatin (30 mM). Similar levels of normalized firefly
luciferase activity were observed (Figure 4D) in DMSO and
cisplatin treated cells indicating that cisplatin treatment of talin
overexpressing cells does not lead to activation of the minimal TK
promoter.
A binding partner of talin currently linked to regulation of cell
survival, proliferation and motility is FAK [29,36,37]. Whether
FAK may be involved in NF-kB signaling induced by cisplatin was
not clear because the levels of active FAK were found to be similar
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However, FAK activity has been demonstrated to be induced by
overexpression of talin [20,21] and FAK has been shown to
regulate NF-kB activity in endothelial cells [38]. We tested
whether FAK is required for talin overexpression to induce NF-kB
signaling following exposure to cisplatin in oral carcinomas. HN12
cells were transfected with the NF-kB firefly luciferase reporter, the
renilla luciferase reporter, talin cDNA and either control or FAK
siRNA oligos. The transfectants were replated onto carcinoma
matrix and treated with cisplatin (1 mM) or DMSO for 24 hours.
The renilla normalized firefly luciferase activity was measured
(Figure 4E). The FAK siRNA reduced NF-kB nuclear activity by
56% in the cisplatin treated talin overexpressing cells compared to
the control siRNA transfectants. Our data demonstrates that FAK
is important for talin to regulate NF-kB activity prior to and
following treatment with cisplatin.
Since talin overexpression regulates NF-kB activity in cisplatin
treated HN12 cells adherent to carcinoma matrix, we subsequent-
ly studied whether talin overexpression regulates cisplatin induced
proliferation in a matrix-specific manner. For these experiments,
Figure 4. Adhesion to carcinoma matrix and talin overexpression regulate NF-kB activity after treatment with cisplatin. A. HN12 cell
transfectants ( (NF-kB)4 firefly luciferase together with renilla luciferase) adherent to carcinoma matrix or collagen I were treated for 24 hours with
30 mM cisplatin or vehicle DMSO. Shown in the bar graph is the mean renilla normalized firefly luciferase activity in arbitrary light units with error bars
indicating standard deviation. B. HN12 cell transfectants (firefly and renilla luciferase constructs with plasmids containing cDNA expression vectors
either cDNA3.1, talin or talin432G) adherent to carcinoma matrix and treated with DMSO for 24 hours. The mean renilla normalized firefly luciferase
activity in arbitrary light units with error bars indicating standard deviation is shown in the bar graph. C. HN12 cells transfected with talin cDNA
expression vector together with (NF-kB)4 firefly luciferase and renilla luciferase were plated onto carcinoma matrix or collagen. Adherent cells were
treated with DMSO or 30 mM cisplatin for 24 hrs and renilla normalized firefly luciferase activity is shown in the bar graph with error bars indicating
standard error. D. HN12 cells transfected with talin cDNA expression vector together with tk-luciferase (lacking the NF-kB regulatory element) and
renilla luciferase adherent to carcinoma matrix were treated with DMSO and 30 mM cisplatin. Renilla normalized firefly luciferase activity is shown in
the bar graph with error bars indicating standard error. E. HN12 cells transfected with (NF-kB)4 firefly luciferase, renilla luciferase and talin cDNA in
combination with either control or FAK siRNA. Carcinoma matrix adherent cells were treated with DMSO or 1 mM cisplatin and renilla normalized
firefly luciferase activity is shown in the bar graph with error bars indicating standard error. Student’s t-test p values *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0021496.g004
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Transfected HN12 cells were replated onto collagen or carcinoma
matrix and treated with DMSO or cisplatin (1 and 30 mM) and
proliferation measured by MTT. In HN12 cells adherent to
carcinoma matrix, the proliferation of wild-type talin expressing
cells treated with either DMSO or cisplatin (1 or 30 mM) was at
levels comparable to control cells treated with DMSO (talin wt:
DMSO, 1 and 30 mM cisplatin proliferation respectively of 1.0-,
1.10-, 1.10-fold, p values for cisplatin treated cells p=0.1 and
0.041) (Figure 5A). Expression of talin432G increased proliferation
1.70-fold (p=0.025) relative to DMSO-treated control transfec-
tants. This level of HN12 proliferation was maintained in
talin432G expressing cells following treatment with cisplatin (1
and 30 mM respectively, 1.89- and 1.99-fold, p=0.020 and 0.043).
Thus, expression of talin432G in oral carcinoma adherent to
carcinoma matrix increases proliferation. This result is consistent
with the observed increase in NF-kB signaling in talin432G
expressing cells.
P130Cas is another integrin effector that was preferentially
detected in integrin complexes of invasive compared to non-
invasive oral carcinomas [17]. In addition, p130Cas is known to
regulate survival, motility and apoptosis [39,40,41,42]. It is
possible that overexpression of a cleavage resistant p130Cas will
similarly influence the ability of the carcinoma matrix to mediate
cisplatin induced proliferation. To test this possibility, we
examined whether overexpression of p130Cas or cleavage-
resistant p130Cas (p130Cas DM) [40] alters cisplatin induced
proliferation of HN12 cells adherent to carcinoma matrix.
Expression of wild-type and cleavage resistant p130Cas failed to
trigger proliferation of HN12 cells (0.95- and 0.89-fold respective-
ly, p=0.37 and 0.32) adherent to carcinoma matrix. Treatment of
HN12 cells expressing wild-type or cleavage-resistant p130Cas
with 1 mM cisplatin increased HN12 proliferation 1.84- and 1.61-
fold relative to DMSO treated control transfectants, (p=0.003 and
0.036) (Figure 5A). Treatment with 30 mM cisplatin decreased
proliferation of p130Cas expressing cells by 28% and cleavage-
resistant p130Cas expressing cells by 34% (compared to controls/
30 mM cisplatin: p130Cas p=0.04, p130Cas DM p=0.067). Thus,
expression of cleavage resistant p130Cas does not recapitulate the
response to 30 mM cisplatin of talin432G expressing HN12 cells
adherent to carcinoma matrix (Figure 5A). Thus, talin 432G and
p130CasDM may regulate cisplatin induced proliferation of
carcinoma matrix adherent cells through different pathways.
It was not clear whether the overexpression of talin or p130Cas
regulates cisplatin induced proliferation in a matrix-specific
manner. Adhesion of HN12 cells to collagen and treatment with
1 mM cisplatin induced proliferation whereas 30 mM cisplatin
inhibited proliferation. NF-kB activity is reduced by 30 mM
cisplatin treatment of collagen adherent cells. Talin overexpression
blocked this reduction of NF-kB activity following treatment with
30 mM cisplatin. Hence, it seemed plausible that talin overexpres-
sion may alter cisplatin induced proliferation on collagen.
Expression of wild-type talin had the same level of proliferation
as control mock transfected cells. Expression of talin in collagen
adherent cells and treatment with 1 mM cisplatin induced
proliferation 3.01-fold (p=0.011). Treatment with 30 mM cisplatin
induced proliferation to a similar level as the 1 mM treated cells,
2.59-fold (p=0.034). Expression of talin432G increased prolifer-
ation 2.43-fold (p=0.009) relative to control mock transfectants a
response that was similar to the carcinoma matrix adherent cells.
However, in cells expressing talin432G, treatment with 1 mM
cisplatin increased proliferation 6.54-fold (p=0.017). Expression of
talin432G and treatment with 30 mM cisplatin increased prolifer-
ation 3.26-fold (p=0.032). Thus overexpression of talin signifi-
cantly increased the proliferation of collagen adherent cells
following treatment with cisplatin.
Examination of the role of p130Cas in HN12 cells adherent to
collagen revealed that expression of p130Cas increased prolifer-
ation 1.84-fold (p=0.05) and p130CasDM increased proliferation
1.36-fold (p=0.109). Following treatment with cisplatin at 1 mM,
Figure 5. Talin and p130Cas control cisplatin induced proliferation of oral carcinoma. HN12 cell transfectants (plasmids containing cDNA
expression vectors either talin, talin432G, p130Cas, p130CasDM (D416E, D748E) and cDNA3.1) were seeded onto A. carcinoma matrix and B. collagen
I. Proliferation was measured following treatment with DMSO or cisplatin (1 and 30 mM) for 48 hours. The mean proliferation is shown with error bars
indicating standard error. The data was normalized to cDNA 3.1 control transfectants treated with DMSO on each substratum. This experiment was
performed 4 times. Statistical comparisons a=control/DMSO, b=control/1 mM, c=control/30 mM. Student’s t-test p values, *p,0.05, **p,0.01,
***p,0.005.
doi:10.1371/journal.pone.0021496.g005
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respectively for wild-type and DM p130Cas (p=0.035, 0.024).
Exposure to 30 mM cisplatin induced proliferation 1.84- and 1.77-
fold for wild-type and DM p130Cas (p=0.043 and 0.053). The
proliferation induced by p130Cas WT and DM at 30 mM cisplatin
were lower than the talin wild-type expressing cells (p=0.024,
0.017). Overexpression of either talin or p130Cas induces HN12
cell proliferation after treatment with cisplatin if adherent to
collagen I (Figure 5B). Our findings suggest that overexpression of
talin regulates both NF-kB nuclear activity and cisplatin induced
proliferation.
A schematic diagram (Figure 6) contains a summary of the
research findings in this study. Oral carcinomas adherent to
carcinomamatrixrespondtoexposuretocisplatinwithproliferation
in a pathway including integrin b1, talin and FAK mediated
regulation of NF-kB signaling. Further studies are required to
understandthe signaling eventslinkingtalin/FAKtoNF-kBand the
matrix components that mediate cisplatin induced proliferation.
Discussion
Oral carcinoma frequently exhibit resistance to cisplatin based
chemotherapy [1]. The mechanisms involved in this resistance are
not completely understood. Our studies focused on oral carcinoma
chemoresistance to cisplatin and revealed that adhesion to the
matrix secreted by oral carcinomas stimulates proliferation
following exposure to cisplatin. Integrin b1 function is required
for adhesion to the carcinoma matrix to induce proliferation in
response to cisplatin. Targeted reduction of talin expression in oral
carcinoma increased proliferation following exposure to cisplatin.
In addition, nuclear NF-kB activity was maintained by adhesion to
the carcinoma matrix following treatment with cisplatin. Interest-
ingly, the overexpression of talin in HN12 cells adherent to
carcinoma matrix is sufficient to induce nuclear NF-kB activity
following exposure to cisplatin. The pathway of talin overexpres-
sion regulating cisplatin induced NF-kB signaling is dependent on
FAK. Our studies show that carcinoma pathways sensitive to the
expression level of talin regulate nuclear NF-kB activity suggesting
that the expression levels of talin in oral carcinoma may influence
the carcinoma response to cisplatin. In summary, adhesion to
carcinoma matrix regulates cisplatin induced proliferation in a
pathway involving integrin b1, talin and FAK and control of NF-
kB signaling.
NF-kB regulates the survival and proliferation of tumor cells
following cancer chemotherapy [30,43]. Genotoxic agents, such as
the chemotherapeutic agent cisplatin, modulate the activity of the
kinase, IKK, that signals for phosphorylation and degradation of
the cytoplasmic NF-kB inhibitor iKBa ˜Interestingly, this IKK
pathway was previously linked to squamous cell carcinoma
progression [44] Degradation of iKBa releases NF-kB from
cytoplasmic retention and permits translocation to the nuclear
compartment [30]. In talin knockdown HN12 cells we failed to
observe changes in iKBa degradation or phosphorylation, or
IKKbexpression or phosphorylation prior to or following exposure
to cisplatin. Our findings fail to support a model wherein talin
regulates the expression level of IKKb to drive high levels of NF-
kB signaling in oral carcinomas following treatment with cisplatin
[45,46].
Other pathways have previously been shown in other cell types
to link integrins to regulation of NF-kB. In endothelial cells,
integrin receptor signaling activates PKA to antagonize PAK
mediated regulation of NF-kB [47]. It is possible that in oral
carcinoma cells there is a similar signaling relationship between
PKA/PAK and NF-kB and hence, PKA pathways are predicted to
disrupt NF-kB activity and oral carcinoma proliferation in
response to cisplatin. Future studies will explore this possibility.
Talin overexpression promoted cisplatin induced proliferation
of oral carcinoma while adherent to collagen, a matrix that fails to
elicit proliferation of the parental HN12 cells in response to 30 mM
cisplatin. Perhaps talin overexpression in the oral carcinomas
induces activation of FAK and a talin/FAK complex regulates
cisplatin induced proliferation. Consistent with this notion, our
data shows that FAK siRNA disrupted cisplatin induced NF-kB
activation in talin overexpressing oral carcinomas. These studies
suggest that FAK inhibitors currently in cancer clinical trials
may also function to disrupt oral carcinoma chemoresistance
[48,49,50]. Future studies will examine this possibility. This
Figure 6. Schematic of oral carcinoma response to cisplatin when adherent to the carcinoma matrix. Cisplatin treatment of oral
carcinoma adherent to carcinoma matrix induces proliferation through integrin b1 dependent pathways. Treatment with cisplatin regulates NF-kB
activity of talin overexpressing oral carcinoma via a FAK-dependent mechanism.
doi:10.1371/journal.pone.0021496.g006
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observations made in endothelial cells during flow [38]. Our
findings suggest that the expression levels of talin and potentially
other integrin effectors, may modulate the efficacy of genotoxic
agents in different microenvironments.
In our studies the targeted disruption of Src failed to alter the
cisplatin induced proliferation of oral carcinoma cells. Our
findings failed to detect a significant role for Src in oral carcinoma
chemosensitivity or chemoresistance. This result contradicts
several recent observations. In embryonic epitheliod cells overex-
pression of constitutively active Src induces chemosensitivity and
apoptosis in response to cisplatin [12]. On the other hand, other
groups have implicated Src activity in resistance to cisplatin. For
example, constitutively active Src in MEFs induces cisplatin
resistance through the function of constitutively active Src in
regulating phosphorylation of connexin 43 resulting in reduced
gap junction function and increased cell survival in response to
cisplatin [19]. Also, in ovarian cancer cells with constitutively
active Src, treatment with pharmacological inhibitors of Src
triggered a reduction in tumor cell survival after cisplatin exposure
[18]. In addition, v-Src induced cisplatin resistance by promoting
repair of cisplatin-DNA adducts in adenocarcinoma cells [51].
The variable requirements for Src may be attributed to differences
in the experimental approaches. Our study focused on Src-
deficient oral carcinomas replated on carcinoma matrix in serum-
free medium. In the Peterson-Roth and Puigvert studies,
overexpression of constitutively active Src
YF was found to control
the response to cisplatin in serum containing medium for cells
replated on tissue culture plastic [12,19]. These observations
suggest that different matrix microenvironments, different cell-
types and variable Src expression levels may each contribute to the
observed Src-dependent phenotypes following exposure to geno-
toxic agents.
The carcinoma matrix in an integrin b1 dependent manner
provides a signal for proliferation in the presence of the genotoxic
agent cisplatin. The integrin b1 ligand in the matrix that is
required for cisplatin induced proliferation is currently not known.
Collagen I, fibronectin, laminin I and basement membrane extract
each failed to function as a substitute for the carcinoma matrix. In
future studies we plan to identify components in the carcinoma
matrix that mediate cisplatin induced proliferation.
Our future studies will explore the oral carcinoma pathways
that link talin to NF-kB signaling and the induction of proliferation
by cisplatin. Further research will study carcinoma matrix
components that confer chemoresistance or chemosensitivity.
Understanding the intracellular pathways and extracellular matrix
factors that coordinate the oral carcinoma response to cisplatin




HN12 cells are Oral Squamous Cell Carcinoma (OSCC)
isolated from the lymph node of a tongue cancer patient [52].
HN12 cells were cultured in DMEM supplemented with fetal
bovine serum, penicillin/streptomycin and fungizone in 10% CO2
[52]. HN12 cells are p53 deficient and resistant to 10 mM cisplatin
in medium containing serum [23].
JHU012 are an OSCC cell line that is sensitive to cisplatin (IC50
of 1 mM) [24]. JHU012 b1 deficient cells were generated using
MISSION TRC shRNA constructs (Sigma) that encode human
integrin b1 shRNA. Lentivirus was produced in 293FT cells
(Invitrogen) using MISSION Lentiviral Packaging Mix (Sigma)
[53]. JHU012 cells were infected with lentiviral clones and stably
transfected cells were selected in the presence of 1.5 mg/mL
puromycin (Cellgro) [54]. Clones were isolated and propagated in
RPMI supplemented with fetal bovine serum, penicillin/strepto-
mycin and 3.0 mg/mL puromycin (Invitrogen) and screened for
integrin b1 knockdown by flow cytometry.
Calcium Phosphate Transfection
HN12 cells [52] were placed in suspension in antibiotic-free
serum-containing DMEM at a density of 1610
5 cells/mL. Cells
were transfected using calcium phosphate precipitation (Invitro-
gen). Three pairs of stealth siRNA duplexes were pooled (50 nM
total, Invitrogen) for each siRNA transfection [55]. Four days after
transfection, cells were harvested for assays and Western blot
analysis.
Coating with Purified Matrix Proteins
Multiwell plates were pre-coated with collagen I, fibronectin,
laminin I or Matrigel at 10 mg/mL and blocked with 0.1% BSA in
PBS [56].
Carcinoma Matrix
HN12 cells were cultured at confluency on collagen I (20 mg/
mL) coated 24 well plates for at least 12 days in complete DMEM
supplemented with ascorbic acid (50 mg/mL). Matrices were
denuded of cells as previously described [17,57,58].
MTT Proliferation Assay
HN12 cells were resuspended in serum-free medium then
4610
4 cells added to wells in a 24-well plate coated with matrix
proteins. Adherent cells were treated with vehicle DMSO (final
concentration less than 0.07%) or cisplatin (1 and 30 mM) for
48 hours. Tumor cell proliferation was measured by MTT and
data normalized to vehicle DMSO-treated cells. During patient
chemotherapy, serum concentrations of cisplatin are approxi-
mately 10 mM.
The MTT assay was performed with the reagent (3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) (ATCC).
The absorbance at 570 nm was measured in a multiwell plate
reader (Biotek, synergy2). MTT reagent in the absence of cells was
background. Cells adherent to collagen I (10 mg/mL) were treated
with pharmacological inhibitors for 48 hours. Cisplatin (EMD
chemicals), MG-132, LY294002, ZVAD-FMK and PD98059
(Calbiochem) were resuspended in vehicle DMSO (Sigma). NF-kB
pathway inhibitors IKKb peptide inhibitor, p50 NLS peptide SN50
and IKK scrambled peptide (Biomol) were resuspended in DMSO.
Immunofluorescence Staining
HN12 cells (3610
4) were seeded onto collagen I (10 mg/mL)
coated glass coverslips in serum-free medium in 24 well tissue
culture plates. The next day, adherent cells were treated with
cisplatin (1 and 30 mM) or DMSO. Two days later the cells were
fixed (5% sucrose 4% formaldehyde in PBS, pH 7.2), permeabi-
lized with 0.4% Triton X-100 in PBS for 5 minutes, blocked with
3% BSA, 150 mM glycine, pH 7.2 for 30 minutes at room
temperature. The blocked cells were stained with Ki67 (mouse,
BD Biosciences) and Donkey anti-mouse Cy3-conjugated second-
ary antibody (Jackson Immunoresearch). Slips were mounted onto
glass slides in a drop of prolong gold (Invitrogen) containing DAPI.
Fluorescent images were acquired and overlayed using an inverted
microscope (Olympus IX81) linked to Slidebook (Intelligent
Imaging Innovations) software. The overlayed images were
imported into Adobe Photoshop to generate the composite.
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The cell surface expression levels of integrin subunits were
determined using direct immunofluorescence staining [59]. Cells
were resuspended in FACS buffer (1% fetal bovine serum in PBS,
pH 7.2) at a concentration of 1610
6 cells/ml (Invitrogen).
Phycoerythrin-conjugated anti-integrin antibodies and isotype
controls (BD Biosciences) were incubated with the cells for 1 hr
on ice. Cells were analyzed using a FACSArray bioanalyzer (BD
Biosciences) [60]. Mean fluorescence intensity was determined
using WinMDI 2.9 software (The Scripps Research Institute, La
Jolla, CA).
Luciferase Assays
HN12 cells were transfected with plasmids containing (NF-kB)4
firefly luciferase (10 mg) and thymidine kinase renilla luciferase
(5 mg) (BD Biosciences Clontech), or co-transfected with plasmids
(1 mg) containing a eukaryotic expression vector for the following
cDNAs talin, talin432G [35], p130Cas or p130CasDM (D416E,
D748E) [40,41]. Two days later, the transfectants were seeded
onto either carcinoma matrix or collagen I. Adherent cells were
incubated with vehicle DMSO or cisplatin for 24 hours, washed
and lysates prepared using passive lysis buffer and the firefly and
renilla luciferase activities were measured using luciferase assay
reagents (Stop-N-Glo kit, Promega) in a luminometer (Berthold
FB12) [61].
Western Blotting
Whole cell lysates were prepared in 5X SDS sample buffer.
Lysates with equivalent levels of actin were tested for the protein
levels of the siRNA target. The following antibodies were used
talin (Sigma), Src (Upstate Biotechnology), vinculin (Sigma), actin
(Sigma) and HRP conjugated secondary antibody (GE Health-
care). The blots were incubated with chemiluminescence ECL
reagent (Amersham ECL plus, GE Healthcare) and exposed to
Amersham hyperfilm (GE Healthcare) that was developed using a
Konica Minolta automatic film developer (Model SRX-101A).
The autoradiograms were scanned and images imported into
Adobe Photoshop to quantitate the band intensities.
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